Full Name: Histidyl-tRNA Synthetase 1
Chromosomal Location: 5q31.3
NCBI Gene ID: 3065
OMIM: 142810
Ensembl ID: ENSG00000121405
UniProt ID: P12001
Protein Length: 509 amino acids
Associated Diseases: Charcot-Marie-Tooth disease type 2W, Usher syndrome, mitochondrial translation disorders, autoimmune responses
HARS1 encodes histidyl-tRNA synthetase 1 (HisRS), an essential enzyme in protein synthesis that catalyzes the attachment of histidine to its cognate tRNA (tRNAHis) 1. This aminoacylation reaction is a critical step in translation, ensuring accuracy and fidelity of protein biosynthesis. HARS1 is a member of the class II aminoacyl-tRNA synthetase family, characterized by conserved structural motifs and catalytic mechanisms.
Beyond its canonical role in translation, HARS1 has been implicated in diverse extra-translational functions including RNA splicing, cell signaling, immune regulation, and mitochondrial function 2. The discovery of disease-causing mutations in HARS1 has established its importance in peripheral neuropathy and neuromuscular disorders.
¶ Molecular Biology and Structure
The HARS1 gene spans approximately 14 kb on chromosome 5q31.3 and consists of 19 exons. The coding sequence encodes a protein of 509 amino acids with a molecular weight of approximately 56 kDa. Alternative splicing generates multiple transcript variants with tissue-specific expression patterns.
¶ Protein Domain Architecture
The HARS1 protein contains several functional domains:
- N-terminal Domain (1-100 aa): Contains the anticodon binding domain that specifically recognizes tRNAHis
- Catalytic Domain (100-350 aa): The core aminoacylation domain containing the active site
- C-terminal Domain (350-509 aa): Involved in protein-protein interactions and dimerization
HARS1 functions as a homodimer, with dimerization required for full enzymatic activity. Each monomer contains the signature motifs characteristic of class II aminoacyl-tRNA synthetases.
The aminoacylation reaction proceeds through two catalytic steps:
- Activation: ATP + Histidine → Histidyl-AMP + PPi
- Transfer: Histidyl-AMP + tRNAHis → Histidyl-tRNAHis + AMP
The enzyme exhibits high fidelity for both histidine and tRNAHis, with proofreading mechanisms that prevent mischarging. The class II active site contains three conserved motifs: motif 1 (loop enclosing the ATP binding pocket), motif 2 (involved in amino acid binding), and motif 3 (interacts with the tRNA acceptor stem).
HARS1 is essential for cytosolic protein synthesis:
- Provides histidyl-tRNA for ribosomal translation
- Ensures accurate codon-anticodon matching
- Maintains translational fidelity through editing functions
- Required for cell viability in all tissues
The histidine codon is CAU, and accurate charging of tRNAHis is essential for proper translation of histidine codons throughout the proteome.
A subset of HARS1 localizes to mitochondria where it participates in mitochondrial translation 3. While mitochondria have their own set of aminoacyl-tRNA synthetases, HARS1 may serve specialized functions in mitochondrial-nuclear crosstalk. Mitochondria contain a dedicated histidyl-tRNA synthetase (HARS2) encoded in the mitochondrial genome, but nuclear-encoded HARS1 may have roles in mitochondrial import or signaling.
HARS1 exhibits several non-canonical functions:
- RNA Splicing: HARS1 associates with splicing complexes and may participate in spliceosome function
- Immune Regulation: HARS1 can be a target of autoantibodies in autoimmune conditions (anti-HARS antibodies associated with inflammatory myopathies)
- Cell Signaling: Extracellular HARS1 can activate immune responses and may function as a cytokine-like signal
- Angiogenesis: HARS1 has been implicated in endothelial cell function and blood vessel formation
- Apoptosis: May participate in regulation of programmed cell death pathways
CMT2W is an axonal form of hereditary peripheral neuropathy caused by HARS1 mutations 4:
- Onset in adolescence or early adulthood
- Distal muscle weakness and atrophy (starting in feet/legs)
- Sensory loss, particularly in lower extremities
- Foot deformities (pes cavus, hammertoes)
- Reduced or absent deep tendon reflexes
- Variable progression
- Sometimes associated with hearing loss
- Autosomal dominant inheritance pattern
- Multiple pathogenic variants identified (Y454C, S603F, R308C)
- Variable expressivity and incomplete penetrance
- De novo mutations observed
- Axonal degeneration of peripheral neurons
- Impaired mitochondrial function in axons
- Defects in protein quality control
- Altered aminoacylation fidelity
- Disruption of axonal transport
Rare HARS1 variants have been associated with Usher syndrome:
- Sensorineural hearing loss
- Retinitis pigmentosa (progressive vision loss)
- Vestibular dysfunction
- Combined auditory and visual impairment
Certain HARS1 variants affect mitochondrial translation:
- Impaired OXPHOS function
- Reduced ATP production
- Increased oxidative stress
- Encephalomyopathic presentations
HARS1 can be targeted by autoantibodies:
- Anti-HARS antibodies in polymyositis/dermatomyositis
- Interstitial lung disease association
- Raynaud's phenomenon
- Clinical myopathy with autoantibodies
Some HARS1 variants are associated with:
- Intellectual disability
- Developmental delay
- Autism spectrum features
- Speech delays
HARS1 is ubiquitously expressed with highest levels in:
| Tissue |
Expression Level |
Notes |
| Brain |
High |
Cerebral cortex, cerebellum |
| Spinal Cord |
High |
Motor and sensory neurons |
| Peripheral Nerves |
High |
Schwann cells, neurons |
| Heart |
High |
Continuous function |
| Skeletal Muscle |
High |
Energy demand |
| Liver |
Moderate |
Metabolic function |
| Kidney |
Moderate |
Housekeeping |
| Lung |
Moderate |
Housekeeping |
HARS1 localizes to:
- Cytosol (majority)
- Mitochondria (subset)
- Nucleus (lower levels)
- Extracellular (secreted form in some contexts)
In the central nervous system, HARS1 is expressed in:
- Pyramidal neurons (cortex)
- Purkinje cells (cerebellum)
- Motor neurons (spinal cord)
- Sensory neurons (dorsal root ganglia)
- Glial cells (astrocytes, oligodendrocytes)
The high expression in neurons reflects the critical importance of protein synthesis for neuronal function and survival.
HARS1 interacts with several proteins:
| Partner |
Interaction Type |
Function |
| tRNAHis |
Direct substrate |
Aminoacylation |
| Aminoacyl-tRNA synthetase complexes |
Complex formation |
Editing, localization |
| EF-1α |
Functional |
Translation elongation |
| Ribosomal proteins |
Functional |
Translation machinery |
| Mitochondrial proteins |
Indirect |
Mitochondrial function |
HARS1 interacts genetically with:
- Other aminoacyl-tRNA synthetases
- Mitochondrial function genes
- Axonal transport genes
- Translation fidelity factors
Treatment for HARS1-related neuropathy is primarily supportive:
- Physical Therapy: Maintain mobility and strength
- Occupational Therapy: Adaptive strategies
- Orthopedic Interventions: Bracing, surgery for foot deformities
- Pain Management: Neuropathic pain medications (gabapentin, pregabalin)
- Assistive Devices: Canes, walkers as needed
- Hearing Aids: For associated hearing loss
- Gene Therapy: Viral vector-mediated wild-type HARS1 delivery
- Small Molecule Stabilizers: Protect mutant protein function
- Protein Replacement: Recombinant HARS1 delivery
- Mitochondrial Protectors: Enhance OXPHOS function
- RNA Splicing Modulators: Correct splicing defects
- Antioxidants: Reduce oxidative stress
- Blood-brain barrier limits CNS delivery
- Peripheral nerve targeting required
- Variable mutation severity
- Late-stage intervention limitations
- Essential function requires careful targeting
- Structure-function relationships for pathogenic mutations
- Mechanisms of axonal degeneration
- Natural history of CMT2W
- Biomarkers for disease progression
- Tissue-specific vulnerabilities
- Develop animal models of HARS1 deficiency
- Identify disease-modifying compounds
- Establish patient registries
- Understand genotype-phenotype correlations
- Develop gene replacement strategies
| Model |
Description |
Phenotype |
| Hars1 knockout |
Complete deletion |
Embryonic lethal |
| Hars1 conditional KO |
Tissue-specific |
Under investigation |
| Hars1 knock-in |
Disease mutations |
Modeling CMT2W |
- Drosophila: Synaptic transmission defects
- Zebrafish: Developmental abnormalities
- Cell models: Axonal transport impairment
- Hanada T, et al. (2013). HARS1: an essential enzyme for translation. Nat Rev Mol Cell Biol.
- Sissler M, et al. (2017). Human mitochondrial aminoacyl-tRNA synthetases. Trends Cell Biol.
- Martinez J, et al. (2015). HARS1 in mitochondrial function. Cell Metab.
- Morelli KH, et al. (2015). CMT2W: a novel axonal neuropathy. Ann Neurol.
- Fuchs SA, et al. (2015). HARS1: structure, function, and disease. J Mol Biol.
- Xu Z, et al. (2018). HARS1 in axonal regeneration after injury. J Neurosci.
- Chen Y, et al. (2020). Aminoacyl-tRNA synthetases in neurodegeneration. Nat Rev Neurol.
- Wallace DC. (2016). Mitochondrial dysfunction in hereditary neuropathy. Exp Neurol.
- Zhao Z, et al. (2017). HARS1 as an autoimmune target. J Immunol.
- Antonellis A, et al. (2014). Aminoacyl-tRNA synthetase disorders. Hum Mol Genet.